Abstract:Background: Clear cell renal cell carcinoma (ccRCC) is an aggressive urological cancer that originates from the proximal tubular epithelium. As one of the most common post-translational modification, protein arginine methylation plays a pivotal role in various cancer-associated biological functions, especially in cancer immunity. Therefore, constructing a protein arginine methylation-related prognostic signature would be beneficial in guiding better personalized clinical management for patients with ccRCC. Methods: Based on the multi-omics profiling of the expression levels of eight protein arginine methyltransferases (PRMTs) in 763 ccRCC samples (from TCGA, CPTAC, EMBL, and ICGC databases), we established a scoring system with machine-learning algorithms to quantify the modification patterns on clinical and immunological characterizations of individual ccRCC patient, which was termed as PRMTScore. Moreover, we utilized two external clinical cohorts receiving immunotherapy (n=302) to validate the reliability of the PRMTScore system. Multiplex immunohistochemistry (mIHC) was performed to characterize the cellular composition of 30 paired ccRCC samples. The proteomic profiling of 232 ccRCC samples obtained from Fudan University Shanghai Cancer Center (FUSCC) was analyzed to validate the protein expression of PRMT5 in ccRCC. Finally, CCK-8, transwell, and wound healing assays were conducted to elucidate the role of PRMT5 in ccRCC in vitro. Results: A total of 763 ccRCC patients with available multi-omics profiling were stratified into two clusters (PRMTCluster A and B) with distinctive prognosis, genomic alterations, tumor microenvironment (TME) characteristics, and fundamental biological mechanisms. Subsequently, protein arginine methylation-related prognostic signature (PRMTScore) was constructed and consisted of SLC16A12, HRH2, F2RL3, and SAA1. The PRMTScore showed remarkable differences in outcomes, immune and stromal fractions, expressions of immune checkpoints, the abundance of immune cells, and immunotherapy response in ccRCC patients. Additionally, preliminary insights unveiled the tumor-suppressive role of PRMT5 in ccRCC, and the signal of PRMT5low significantly predicted aggressive prognosis and the high abundance of PD1+ CD8+ cells in ccRCC. Conclusion: We constructed a PRMTScore system, which showed the potent ability to assess the prognosis, TME characteristics, and immunotherapy response for patients with ccRCC. Moreover, this is the first study to propose that PRMT5 acts as a cancer suppressor in ccRCC.

A comprehensive investigation of PRMT5 in the prognosis and ion channel features of lung cancer

Proteomic and Phosphoproteomic Maps of Lung Squamous Cell Carcinoma from Chinese Patients.

Prognostic Risk Model and Tumor Immune Environment Modulation of M5c-Related LncRNAs in Pancreatic Ductal Adenocarcinoma

Protein arginine methyltransferase 5 promotes lung cancer metastasis via the epigenetic regulation of miR-99 family/FGFR3 signaling

PRMT5 Inhibition Promotes PD-L1 Expression and Immuno-Resistance in Lung Cancer

PRMT5 Promotes EMT Through Regulating Akt Activity in Human Lung Cancer

PRMT5 activates KLF5 by methylation to facilitate lung cancer

Protein Arginine Methyltransferases Refine the Classification of Clear Cell Renal Cell Carcinoma with Distinct Prognosis and Tumor Microenvironment Characteristics.

The methylation induced by protein arginine methyltransferase 5 promotes tumorigenesis and progression of lung cancer

The Methylation Induced by Protein Arginine Methyltransferase 5 Promotes Tumorigenesis and Progression of Lung Cancer.

PRMT5 Enables Robust STAT3 Activation via Arginine Symmetric Dimethylation of SMAD7

SLC2A5 Correlated with Immune Infiltration: A Candidate Diagnostic and Prognostic Biomarker for Lung Adenocarcinoma

PRMT5 prognostic value in cancer

m5C-Related lncRNAs Predict Overall Survival of Patients and Regulate the Tumor Immune Microenvironment in Lung Adenocarcinoma

Prognostic Value and Related Regulatory Networks of MRPL15 in Non-Small-Cell Lung Cancer.

High PRMT5 Expression is Associated with Poor Overall Survival and Tumor Progression in Bladder Cancer

Overexpression of MRPL19 in Predicting Poor Prognosis and Promoting the Development of Lung Adenocarcinoma.

Protein arginine methyltransferase 5 regulates multiple signaling pathways to promote lung cancer cell proliferation

Dysregulated YY1/PRMT5 axis promotes the progression and metastasis of laryngeal cancer by targeting Hippo pathway

Protein Arginine Methyltransferase 5: a Potential Cancer Therapeutic Target

PRMT1 in human neoplasm: cancer biology and potential therapeutic target